Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01938404 · ClinicalTrials.gov registry record
Octaplas Adult TTP Trial
A clinical trial, sponsored by Octapharma.
- Terminated
- Registry status
- 1
- Enrollment target
NCT01938404 is a clinical trial that was terminated before completion, run by Octapharma. The registered enrollment target is 1 participants.
The verdict
NCT01938404 was terminated before completion, sponsored by Octapharma.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
To assess and evaluate the safety of octaplas™ in comparison to standard plasma product (e.g., fresh frozen plasma (FFP) and other approved plasma products used within 24 hours of thawing) used in the treatment of TTP, in patients undergoing Therapeutic Plasma Exchange, with a special emphasis on the occurrence of thromboembolic events (TEEs).
Interventions
- BIOLOGICAL Octaplas
- DRUG Standard Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-06-06 |
| Est. Completion | 2017-08-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01938404
The ClinicalTrials.gov registry entry for NCT01938404 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Octaplas is the first listed.
NCT01938404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01938404 about?
NCT01938404 is a clinical study titled "Octaplas Adult TTP Trial". To assess and evaluate the safety of octaplas™ in comparison to standard plasma product (e.g., fresh frozen plasma (FFP) and other approved plasma products used within 24 hours of thawing) used in the treatment of TTP, in patients undergoing Therapeutic Plasma Exchange, with a special emphasis on th...
What is the current status of trial NCT01938404?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2017-06-06. Estimated completion is 2017-08-02.
What interventions are being tested in trial NCT01938404?
The interventions under investigation include: Octaplas (BIOLOGICAL), Standard Plasma (DRUG).
Who is sponsoring clinical trial NCT01938404?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.